Triveni Bio Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
45
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$65M
- Investors
-
14
Triveni Bio General Information
Description
Operator of a clinical-stage biotechnology company designed to create antibody-based therapies targeting immunological and inflammatory diseases. The company offers a genetics-informed antibody discovery and engineering platform, deep insights from human genetic data, and biologics targeting validated disease mechanisms, enabling patients and clinicians dealing with immune and inflammatory disorders to access potentially more effective and precise treatments.
Contact Information
Website
www.triveni.bioCorporate Office
- 99 Coolidge Avenue
- Suite 450
- Watertown, MA 02472
- United States
Corporate Office
- 99 Coolidge Avenue
- Suite 450
- Watertown, MA 02472
- United States
Triveni Bio Timeline
Triveni Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series C) | 17-Jun-2026 | $65M | Completed | Clinical Trials - Phase 2 | ||
| 3. Later Stage VC (Series B) | 18-Jun-2025 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series A) | 26-Oct-2023 | $91.6M | $117M | Completed | Startup | |
| 1. Seed Round | $25M | $25M | Completed | Startup |
Triveni Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A-2 | ||||||||
| Series A-1 | ||||||||
| Seed-3 | ||||||||
| Seed-2 | 6,676,725 | $0.000010 | $1.5 | $1.5 | 1x | $1.5 | 1.75% | |
| Seed-1 | 1,000,000 | $0.000010 | $0.4 | $0.4 | 1x | $0.4 | 0.26% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Triveni Bio Comparisons
Industry
Financing
Details
Triveni Bio Competitors (60)
One of Triveni Bio’s 60 competitors is Centrose, a Venture Capital-Backed company based in Madison, WI.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Centrose | Venture Capital-Backed | Madison, WI | ||||
| Xalud Therapeutics | Venture Capital-Backed | New York, NY | ||||
| Seismic Therapeutic | Venture Capital-Backed | Watertown, MA | ||||
| Aviceda Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA |
Triveni Bio Patents
Triveni Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026151944-A1 | Anti-il-13 antibodies and uses thereof | Pending | 10-Jan-2025 | ||
| WO-2026151948-A1 | Anti-il-13 antibodies and uses thereof | Pending | 10-Jan-2025 | ||
| WO-2026151954-A1 | Klk5/7 + il-13 targeting antibodies and uses thereof | Pending | 10-Jan-2025 | ||
| WO-2026085370-A2 | Dual inhibitor trypsin antibodies and uses thereof | Pending | 16-Oct-2024 | ||
| WO-2026085370-A3 | Dual inhibitor trypsin antibodies and uses thereof | Pending | 16-Oct-2024 | C07K16/40 |
Triveni Bio Signals
Triveni Bio Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Ascenta Capital | Venture Capital | Minority | ||
| Janus Henderson Investors | Asset Manager | Minority | ||
| Deep Track Capital | Venture Capital | Minority | ||
| Fidelity Management & Research Company | Asset Manager | Minority | ||
| Goldman Sachs Asset Management | Asset Manager | Minority |
Triveni Bio Acquisitions (1)
Triveni Bio’s most recent deal was a Merger/Acquisition with Amagma Therapeutics. The deal was made on 26-Nov-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Amagma Therapeutics | 26-Nov-2023 | Merger/Acquisition | Drug Discovery |
Triveni Bio FAQs
-
When was Triveni Bio founded?
Triveni Bio was founded in 2019.
-
Where is Triveni Bio headquartered?
Triveni Bio is headquartered in Watertown, MA.
-
What is the size of Triveni Bio?
Triveni Bio has 45 total employees.
-
What industry is Triveni Bio in?
Triveni Bio’s primary industry is Drug Discovery.
-
Is Triveni Bio a private or public company?
Triveni Bio is a Private company.
-
What is the current valuation of Triveni Bio?
The current valuation of Triveni Bio is .
-
What is Triveni Bio’s current revenue?
The current revenue for Triveni Bio is .
-
How much funding has Triveni Bio raised over time?
Triveni Bio has raised $297M.
-
Who are Triveni Bio’s investors?
Ascenta Capital, Janus Henderson Investors, Deep Track Capital, Fidelity Management & Research Company, and Goldman Sachs Asset Management are 5 of 14 investors who have invested in Triveni Bio.
-
Who are Triveni Bio’s competitors?
Centrose, Xalud Therapeutics, Seismic Therapeutic, Aviceda Therapeutics, and Inovio Pharmaceuticals are some of the 60 competitors of Triveni Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process